Fusion Pharmaceuticals (FUSN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

FUSN Stock Forecast

Fusion Pharmaceuticals stock forecast is as follows: an average price target of $15.25 (represents a -29.23% downside from FUSN’s last price of $21.55) and a rating consensus of 'Hold', based on 11 wall street analysts offering a 1-year stock forecast.

FUSN Price Target

The average price target for Fusion Pharmaceuticals (FUSN) is $15.25 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $6.00. This represents a potential -29.23% downside from FUSN's last price of $21.55.

FUSN Analyst Ratings

Hold

According to 11 Wall Street analysts, Fusion Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for FUSN stock is 2 'Strong Buy' (18.18%), 2 'Buy' (18.18%), 6 'Hold' (54.55%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

Fusion Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 19, 2024	Matthew Harrison	Morgan Stanley	$21.00	$21.18	-0.85%	-2.55%
Mar 19, 2024	Suji Jeong	Jefferies	$21.00	$21.18	-0.85%	-2.55%
Sep 29, 2023	Jeff Jones	Oppenheimer	$13.00	$2.60	400.00%	-39.68%
Nov 30, 2022		Leerink Partners	$6.00	$2.16	177.78%	-72.16%

The latest Fusion Pharmaceuticals stock forecast, released on Mar 19, 2024 by Matthew Harrison from Morgan Stanley, set a price target of $21.00, which represents a -0.85% decrease from the stock price at the time of the forecast ($21.18), and a -2.55% decrease from FUSN last price ($21.55).

Fusion Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$21.00
Last Closing Price	$21.55	$21.55	$21.55
Upside/Downside	-100.00%	-100.00%	-2.55%

In the current month, the average price target of Fusion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fusion Pharmaceuticals's last price of $21.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 16, 2024	Cowen & Co.		Hold	Downgrade
Mar 20, 2024	Wedbush	Sector Perform	Sector Perform	Hold
Mar 19, 2024	Leerink Partners		Market Perform	Downgrade
Mar 04, 2024	Wedbush	Strong Buy	Strong Buy	Hold
Jan 26, 2024	Wedbush	Strong Buy	Strong Buy	Hold
Dec 27, 2023	Raymond James	Outperform	Strong Buy	Upgrade
Dec 27, 2023	RBC Capital	Strong Buy	Strong Buy	Hold
Jun 23, 2023	B. Riley Securities		Neutral	Initialise
Jun 23, 2023	Compass Point		Sell	Initialise
Jun 23, 2023	Piper Sandler		Neutral	Initialise
Jun 23, 2023	Raymond James		Outperform	Initialise
Jun 23, 2023	Stephens		Equal-Weight	Initialise
Jun 23, 2023	BTIG		Buy	Initialise
Nov 30, 2022	SVB Leerink		Outperform	Initialise

Fusion Pharmaceuticals's last stock rating was published by Cowen & Co. on Apr 16, 2024. The company Downgrade its FUSN rating from "null" to "Hold".

Fusion Pharmaceuticals Financial Forecast

Fusion Pharmaceuticals Revenue Forecast

	Dec 27	Oct 27	Jul 27	Mar 27	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Oct 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$28.00K	$140.00K	-	-	$585.00K	-	-
Avg Forecast	$1.79M	$597.70K	-	-	-	-	-	-	-	-	-	-	$193.50K	$186.00K	$192.67K	$168.50K	$412.40K	$86.00K	$75.00K	$8.57M	$17.00K	$100.00K	$137.50K	$1.42M	$260.50K	$3.33M
High Forecast	$1.79M	$597.70K	-	-	-	-	-	-	-	-	-	-	$193.50K	$186.00K	$192.67K	$168.75K	$793.08K	$86.00K	$75.00K	$8.57M	$17.00K	$100.00K	$137.50K	$1.42M	$260.50K	$3.33M
Low Forecast	$1.79M	$597.70K	-	-	-	-	-	-	-	-	-	-	$193.50K	$186.00K	$192.67K	$168.25K	$31.72K	$86.00K	$75.00K	$8.57M	$17.00K	$100.00K	$137.50K	$1.42M	$260.50K	$3.33M
# Analysts	1	1	-	-	-	-	-	-	-	-	-	-	1	1	2	3	6	4	4	4	2	2	2	2	3	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	8.24%	-	-	0.41%	-	-

Fusion Pharmaceuticals's average Quarter revenue forecast for Jul 23 based on 4 analysts is $75.00K, with a low forecast of $75.00K, and a high forecast of $75.00K. FUSN's average Quarter revenue forecast represents a 167.86% increase compared to the company's last Quarter revenue of $28.00K (Mar 23).

Fusion Pharmaceuticals EBITDA Forecast

	Dec 27	Oct 27	Jul 27	Mar 27	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Oct 21	Dec 20
# Analysts	1	1	-	-	-	-	-	-	-	-	-	-	1	1	2	3	6	4	4	4	2	2	2	2	3	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-27.91M	-	-	$-23.08M	$-23.79M	-	-	$-20.32M	-	-
Avg Forecast	$-358.62K	$-119.54K	-	-	-	-	-	-	-	-	-	-	$-38.70K	$-37.20K	$-38.53K	$-33.70K	$-82.48K	$-17.20K	$-15.00K	$-1.71M	$-3.40K	$-20.00K	$-27.50K	$-20.50M	$-52.10K	$-666.67K
High Forecast	$-358.62K	$-119.54K	-	-	-	-	-	-	-	-	-	-	$-38.70K	$-37.20K	$-38.53K	$-33.65K	$-6.34K	$-17.20K	$-15.00K	$-1.71M	$-3.40K	$-20.00K	$-27.50K	$-16.40M	$-52.10K	$-666.67K
Low Forecast	$-358.62K	$-119.54K	-	-	-	-	-	-	-	-	-	-	$-38.70K	$-37.20K	$-38.53K	$-33.75K	$-158.62K	$-17.20K	$-15.00K	$-1.71M	$-3.40K	$-20.00K	$-27.50K	$-24.60M	$-52.10K	$-666.67K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	338.44%	-	-	13.46%	6998.53%	-	-	0.99%	-	-

undefined analysts predict FUSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fusion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Fusion Pharmaceuticals Net Income Forecast

	Dec 27	Oct 27	Jul 27	Mar 27	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Oct 21	Dec 20
# Analysts	1	1	-	-	-	-	-	-	-	-	-	-	1	1	2	3	6	4	4	4	2	2	2	2	3	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-28.18M	-	-	$-24.29M	$-24.62M	-	-	$-19.91M	-	-
Avg Forecast	$-47.38M	$-45.85M	$-41.29M	$-36.24M	$-35.86M	$-35.30M	$-34.74M	$-34.94M	$-37.41M	$-36.70M	$-34.72M	$-34.33M	$-30.26M	$-30.28M	$-29.53M	$-31.11M	$-28.40M	$-33.52M	$-32.92M	$-25.96M	$-45.94M	$-41.99M	$-43.40M	$-20.74M	$-48.42M	$-15.50M
High Forecast	$-47.38M	$-45.85M	$-41.29M	$-36.24M	$-35.86M	$-35.30M	$-34.74M	$-34.94M	$-37.41M	$-36.70M	$-34.72M	$-34.33M	$-30.26M	$-30.28M	$-22.35M	$-31.11M	$-22.56M	$-33.52M	$-32.92M	$-25.96M	$-45.94M	$-41.99M	$-43.40M	$-16.59M	$-48.42M	$-15.50M
Low Forecast	$-47.38M	$-45.85M	$-41.29M	$-36.24M	$-35.86M	$-35.30M	$-34.74M	$-34.94M	$-37.41M	$-36.70M	$-34.72M	$-34.33M	$-30.26M	$-30.28M	$-35.12M	$-31.11M	$-35.09M	$-33.52M	$-32.92M	$-25.96M	$-45.94M	$-41.99M	$-43.40M	$-24.89M	$-48.42M	$-15.50M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.99%	-	-	0.94%	0.54%	-	-	0.96%	-	-

Fusion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FUSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Fusion Pharmaceuticals SG&A Forecast

	Dec 27	Oct 27	Jul 27	Mar 27	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Oct 21	Dec 20
# Analysts	1	1	-	-	-	-	-	-	-	-	-	-	1	1	2	3	6	4	4	4	2	2	2	2	3	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.63M	-	-	$9.01M	$6.95M	-	-	$8.45M	-	-
Avg Forecast	$20.39M	$6.80M	-	-	-	-	-	-	-	-	-	-	$2.20M	$2.11M	$2.19M	$1.92M	$4.69M	$977.79K	$852.72K	$97.45M	$193.28K	$1.14M	$1.56M	$16.12M	$2.96M	$37.90M
High Forecast	$20.39M	$6.80M	-	-	-	-	-	-	-	-	-	-	$2.20M	$2.11M	$2.19M	$1.92M	$9.02M	$977.79K	$852.72K	$97.45M	$193.28K	$1.14M	$1.56M	$16.12M	$2.96M	$37.90M
Low Forecast	$20.39M	$6.80M	-	-	-	-	-	-	-	-	-	-	$2.20M	$2.11M	$2.19M	$1.91M	$360.68K	$977.79K	$852.72K	$97.45M	$193.28K	$1.14M	$1.56M	$16.12M	$2.96M	$37.90M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.63%	-	-	0.09%	35.96%	-	-	0.52%	-	-

Fusion Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $1.92M, based on 3 Wall Street analysts, with a range of $1.91M to $1.92M. The forecast indicates a -74.88% fall compared to FUSN last annual SG&A of $7.63M (Dec 23).

Fusion Pharmaceuticals EPS Forecast

	Dec 27	Oct 27	Jul 27	Mar 27	Dec 26	Oct 26	Jul 26	Mar 26	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Oct 21	Dec 20
# Analysts	1	1	-	-	-	-	-	-	-	-	-	-	1	1	2	3	6	4	4	4	2	2	2	2	3	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.39	-	-	$-0.45	$-0.55	-	-	$-0.46	-	$-0.32
Avg Forecast	$-0.57	$-0.55	$-0.49	$-0.43	$-0.43	$-0.42	$-0.41	$-0.42	$-0.45	$-0.44	$-0.41	$-0.41	$-0.36	$-0.36	$-0.35	$-0.37	$-0.34	$-0.40	$-0.39	$-0.31	$-0.55	$-0.50	$-0.52	$-0.44	$-0.58	$-0.18
High Forecast	$-0.57	$-0.55	$-0.49	$-0.43	$-0.43	$-0.42	$-0.41	$-0.42	$-0.45	$-0.44	$-0.41	$-0.41	$-0.36	$-0.36	$-0.27	$-0.37	$-0.27	$-0.40	$-0.39	$-0.31	$-0.55	$-0.50	$-0.52	$-0.44	$-0.58	$-0.18
Low Forecast	$-0.57	$-0.55	$-0.49	$-0.43	$-0.43	$-0.42	$-0.41	$-0.42	$-0.45	$-0.44	$-0.41	$-0.41	$-0.36	$-0.36	$-0.42	$-0.37	$-0.42	$-0.40	$-0.39	$-0.31	$-0.55	$-0.50	$-0.52	$-0.44	$-0.58	$-0.18
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.15%	-	-	1.45%	1.00%	-	-	1.04%	-	1.73%

According to undefined Wall Street analysts, Fusion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FUSN previous annual EPS of $NaN (undefined).

Fusion Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RLMD	Relmada Therapeutics	$0.36	$5.67	1475.00%	Buy
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
OLMA	Olema Pharmaceuticals	$6.14	$27.00	339.74%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
BCAB	BioAtla	$1.31	$5.00	281.68%	Buy
CHRS	Coherus BioSciences	$1.71	$6.00	250.88%	Hold
BCYC	Bicycle Therapeutics	$15.14	$43.67	188.44%	Buy
FENC	Fennec Pharmaceuticals	$6.07	$15.75	159.47%	Buy
RAPT	RAPT Therapeutics	$0.84	$2.00	138.10%	Hold
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
NAMS	NewAmsterdam Pharma Company	$26.61	$39.33	47.80%	Buy
HRMY	Harmony Biosciences	$33.63	$48.00	42.73%	Buy
JANX	Janux Therapeutics	$59.61	$70.25	17.85%	Buy
IKNA	Ikena Oncology	$1.62	$1.33	-17.90%	Buy

FUSN Forecast FAQ

Is Fusion Pharmaceuticals a good buy?

No, according to 11 Wall Street analysts, Fusion Pharmaceuticals (FUSN) is considered a 'Hold'. The rating consensus is based on 2 'Strong Buy' and 2 'Buy' recommendations, accounting for 36.36% of FUSN's total ratings.

What is FUSN's price target?

Fusion Pharmaceuticals (FUSN) average price target is $15.25 with a range of $6 to $21, implying a -29.23% from its last price of $21.55. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fusion Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for FUSN stock, the company can go down by -29.23% (from the last price of $21.55 to the average price target of $15.25), down by -2.55% based on the highest stock price target, and down by -72.16% based on the lowest stock price target.

Can Fusion Pharmaceuticals stock reach $30?

FUSN's average twelve months analyst stock price target of $15.25 does not support the claim that Fusion Pharmaceuticals can reach $30 in the near future.

What are Fusion Pharmaceuticals's analysts' financial forecasts?

Fusion Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-141M (high $-141M, low $-141M), average SG&A $0 (high $0, low $0), and average EPS is $-1.681 (high $-1.681, low $-1.681). FUSN's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.39M (high $2.39M, low $2.39M), average EBITDA is $-478K (high $-478K, low $-478K), average net income is $-171M (high $-171M, low $-171M), average SG&A $27.18M (high $27.18M, low $27.18M), and average EPS is $-2.038 (high $-2.038, low $-2.038).

Did the FUSN's actual financial results beat the analysts' financial forecasts?

Based on Fusion Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $2.07M, which missed the average analysts forecast of $9.14M by -77.39%. Apple's EBITDA was $-99.232M, beating the average prediction of $-1.829M by 5325.59%. The company's net income was $-94.897M, missing the average estimation of $-121M by -21.45%. Apple's SG&A was $31.2M, missing the average forecast of $103.97M by -70.00%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-1.442 by -99.90%. In terms of the last quarterly report (Mar 2023), Fusion Pharmaceuticals's revenue was $28K, missing the average analysts' forecast of $8.57M by -99.67%. The company's EBITDA was $-23.079M, beating the average prediction of $-1.714M by 1246.28%. Fusion Pharmaceuticals's net income was $-24.291M, missing the average estimation of $-25.963M by -6.44%. The company's SG&A was $9.01M, missing the average forecast of $97.45M by -90.76%. Lastly, the company's EPS was $-0.45, beating the average prediction of $-0.31 by 45.20%